The calcifediol supplements market is evaluated at US$846.335 million for the year 2020 and is projected to grow at a CAGR of 9.86% to reach a market size of US$1,634.630 million by the year 2027.
Calcifediol supplements are a more advanced and powerful type of vitamin D supplement available on the market. It has been clinically demonstrated to increase vitamin D levels three times quicker and more efficiently than other methods. Calcifediol monohydrate (25-Hydroxyvitamin D3) is a vitamin D3 analogue created by hydroxylation of vitamin D3 (cholecalciferol) using the enzyme cholecalciferol 25-hydroxylase. Advances in vitamin D-rich food items, as well as the presence of major international firms in the regional market, are projected to have a favourable impact on the business. Because customers are becoming more aware of the benefits of eating nutritionally dense foods, foodservice makers are increasingly emphasizing the availability of vitamin-fortified food products.
Consumers today place high importance on immunity, with 69 percent using supplements to boost their immune health. Although vitamin D is well known for its function in bone and muscular health, a growing body of research reveals that it also has substantial immunological advantages, including supporting the immune response and lowering the risk of acute respiratory infections. This opens up a lot of possibilities for dietary supplement companies looking to provide purpose-driven nutritional solutions that help people stay healthy.
Increasing expenditures on advanced pharmaceutical ingredients (API) manufactured in emerging economies such as China and India are expected to keep the calcifediol supplements market growing. Furthermore, the global prevalence of chronic kidney disease (CKD) is increasing as a result of changing dietary patterns and a fast-paced work environment, which is increasing the demand for calcifediol supplements. Because of the advantageous legislation regulating the manufacture and sale of vitamin D analogues and vitamin D3 APIs, leading manufacturers are locating their manufacturing facilities in Europe.
However, as consumers become more aware of the negative effects of inorganic food on people's health, the trend toward organic food market growth has shifted. The growing move toward eating organic foods rather than supplement or fortified foods is expected to limit calcifediol supplements demand and, as a result, hinder the market growth.
Animal feed, pharmaceuticals, and others are the three application segments that make up the global calcifediol supplements market. Broilers, cattle, breeders, and swine are projected to employ calcium and phosphorus absorption in their bodies and calcium mobilization in their bones as an important source of calcium and phosphorus absorption in the animal sector. Additionally, it aids in the improvement of immune cells. Because of its widespread use in health supplements, injectables, and capsules, the pharmaceuticals segment is also expected to develop at a high CAGR during the forecast period.
The largest market, Asia Pacific, accounts for a considerable portion of the global calcifediol supplements market. Vitamin D deficiency is widespread throughout the Asia Pacific, particularly in South-East Asia, followed by North America, implying a significant financial strain on healthcare and personal expenditures for bone treatment, gradually moving people to a superior alternative business of calcifediol supplements. Increasing income levels and significant consumer demand for nutritious and healthy products is anticipated to provide promising prospects for the expansion and development of the region's functional food and beverage products, resulting in increased consumption of vitamin-infused products and, as a result, market growth.
The COVID-19 outbreak caused a substantially positive effect on the calcifediol supplements market. During the coronavirus pandemic, demand for calcifediol supplements soared, owing to customers' tendency to buy in quantity. Bulk purchases, it's been suggested, aren't just a lockdown-induced trend; they're predicted to continue into upcoming years, as consumers try to decrease the number of store trips as a form of social isolation. Even when shopping for supplement goods online, buyers prefer to buy in bulk to get more bang for their buck on shipping fees. Increasing evidence suggests that vitamin D plays a preventive role in lowering the risk and severity of respiratory tract infections (RTIs), particularly in the context of influenza and COVID-19. A multi-centre observational analysis of 537 COVID-19 patients found that those who received calcifediol supplements had a lower mortality rate during the first 30 days of hospitalisation than those who did not.
DSM (Netherlands) and Zhejiang Xinhecheng Co Ltd. (China) inked a contract for the sale and purchase of cholesterol in January 2019. Vitamin D3 is made from cholesterol. This deal assisted the organisation in increasing its total capacity and Vitamin D productivity.
Fermenta Biotech Limited (India) signed a 99-year lease deal with the Gujarat Industrial Development Corporation (GIDC) authority in Ankleshwar, Sayaka in January 2019 to acquire a 40,000-square-meter plot of land for future expansion.
1.1. Market Definition
1.2. Market Segmentation
2. Research Methodology
2.1. Research Data
3. Executive Summary
3.1. Research Highlights
4. Market Dynamics
4.1. Market Drivers
4.2. Market Restraints
4.3. Porters Five Forces Analysis
4.3.1. Bargaining Power of End-Users
4.3.2. Bargaining Power of Buyers
4.3.3. Threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis
5. Calcifediol Supplements Market Analysis, by Application
5.2. Infant Pharmaceuticals
5.3. Animal feed
6. Calcifediol Supplements Market Analysis, by Distribution Channel
6.3. Pharmacies/Health Stores
6.4. Online Retailing
6.5. Other Distribution Channels
7. Calcifediol Supplements Market Analysis, by Geography
7.2. North America
7.3. South America
7.4.1. United Kingdom
7.5. The Middle East and Africa
7.5.1. Saudi Arabia
7.6. Asia Pacific
7.6.4. South Korea
8. Competitive Environment and Analysis
8.1. Major Players and Strategy Analysis
8.2. Emerging Players and Market Lucrativeness
8.3. Mergers, Acquisitions, Agreements, and Collaborations
8.4. Vendor Competitiveness Matrix
9. Company Profiles
9.1. Chemvon Biotechnology Co
9.2. Cayman Chemicals
9.3. Haoyuan Chemexpress Co., Ltd
9.4. Pharmaceutical Research Institute (PRI)
9.5. BOC Sciences
9.9. ApexBio Technology
Chemvon Biotechnology Co
Haoyuan Chemexpress Co., Ltd
Pharmaceutical Research Institute (PRI)
All our studies come with 2 months of analyst support.
We are in compliance with the global privacy laws.